Private company

G1 Therapeutics, Inc.

In its 2024 annual report the company says: “We are a commercial-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. We are exploring the use of trilaciclib in clinical trials to optimize these potential benefits in combination with leading and emerging treatments for patients.”3 It is headquartered in Research Triangle Park, North Carolina.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersResearch Triangle Park, North Carolina1
  • Incorporated inDE2
  • Business address700 Park Offices Drive, Suite 200, Research Triangle Park, Nc 277092
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. COSELA® (trilaciclib), our first product approved by the U.S. Food and Drug Administration (“FDA”), is the first and only therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy and is the first innovation in managing myeloprotection in decades. COSELA (trilaciclib hydrochloride for injection) is also approved by the China National Medical Products Administration ("NMPA") for marketing in mainland China and is commercialized by our partner, Simcere Pharmaceutical Co., Ltd. ("Simcere"), in Greater China (mainland China, Hong Kong, Macau and Taiwan).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-47.9%Operating margin4
-58.1%Net margin4
60.8%Revenue growth, 20234
-135.6%Return on equity4
1.41×Debt to equity4
-$38.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development37¢$43.7M
  • Selling, general and admin60¢$71.1M
  • Income tax3¢$3.1M

Out of $82.5M in revenue.4 The company lost money this year.

Financial statements

Revenue54$82.5M in 2023+82% since 2020
0$25.0M$50.0M$75.0M$100.0M2020: $45.3M$45.3M20202021: $31.5M$31.5M2021−30%2022: $51.3M$51.3M2022+63%2023: $82.5M$82.5M2023+61%
Operating income67854-$39.5M in 2023−35% since 2017
-$150.0M-$100.0M-$50.0M02017: -$61.0M-$61.0M20172018: -$89.3M-$89.3M2018+46%2019: -$129.0M-$129.0M2019+45%2020: -$96.5M-$96.5M2020−25%2021: -$142.5M-$142.5M2021+48%2022: -$136.2M-$136.2M2022−4%2023: -$39.5M-$39.5M2023−71%
Net income67854-$48.0M in 2023−20% since 2017
-$150.0M-$100.0M-$50.0M02017: -$60.1M-$60.1M20172018: -$85.3M-$85.3M2018+42%2019: -$122.4M-$122.4M2019+44%2020: -$99.3M-$99.3M2020−19%2021: -$148.4M-$148.4M2021+49%2022: -$147.6M-$147.6M2022−1%2023: -$48.0M-$48.0M2023−67%
Fiscal year2017201820192020202120222023
Revenue$45.3M5$31.5M4$51.3M4$82.5M4
Research and development$53.9M6$70.7M7$89.0M8$73.3M5$76.2M4$83.3M4$43.7M4
Selling, general and admin$40.0M8$68.5M5$95.7M4$100.4M4$71.1M4
Operating expenses$173.9M4$187.5M4$122.0M4
Operating income-$61.0M6-$89.3M7-$129.0M8-$96.5M5-$142.5M4-$136.2M4-$39.5M4
Income before tax-$147.4M4-$145.9M4-$44.9M4
Income tax$1.4M5$925.0K4$1.7M4$3.1M4
Net income-$60.1M6-$85.3M7-$122.4M8-$99.3M5-$148.4M4-$147.6M4-$48.0M4
Earnings per share-$2.625-$3.544-$3.384-$0.934
Earnings per share (diluted)-$2.625-$3.544-$3.384-$0.934
Shares (weighted, basic)41.9M shares443.6M shares451.7M shares4
Shares (weighted, diluted)41.9M shares443.6M shares451.7M shares4

Compare G1 Therapeutics, Inc. with another company

Corporate structure

G1 Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of G1 Therapeutics, Inc.

  • Beryl Capital Management LLC Filed SC 13G/A on G1 Therapeutics, Inc., latest Nov 13, 2024 (2 filings since Aug 19, 2024)
  • Fredric N. Eshelman Filed SC 13D/A on G1 Therapeutics, Inc., latest Feb 21, 2024
  • Fisher Asset Management, LLC Filed SCHEDULE 13G on G1 Therapeutics, Inc., latest Feb 5, 2024
  • VANGUARD GROUP INC Filed SC 13G/A on G1 Therapeutics, Inc., latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • State Street Corporation Filed SC 13G/A on G1 Therapeutics, Inc., latest Feb 3, 2023 (4 filings since Oct 12, 2021)
  • JPMorgan Chase Filed SC 13G/A on G1 Therapeutics, Inc., latest Dec 6, 2022 (2 filings since Jan 21, 2022)
  • G1 Therapeutics, Inc. Research Triangle Park, North Carolina

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What G1 Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$2.3M4 Dec 31, 2023$1.8M4 Dec 31, 2022+28.1%
Property and equipment, net$1.5M4 Dec 31, 2023$2.0M4 Dec 31, 2022−25.8%
Operating-lease assets (leased space)$4.9M4 Dec 31, 2023$6.0M4 Dec 31, 2022−17.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$32.2M4 Dec 31, 2023$94.6M4 Dec 31, 2022−65.9%
Marketable securities, current$49.9M4 Dec 31, 2023$50.5M4 Dec 31, 2022−1.1%
Debt securities available for sale$49.9M4 Dec 31, 2023$50.5M4 Dec 31, 2022−1.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$12.4M4 Dec 31, 2023$16.2M4 Dec 31, 2022−23.1%
Raw materials$2.4M4 Dec 31, 2023$2.8M4 Dec 31, 2022−13.2%
Work in process$9.6M4 Dec 31, 2023$10.2M4 Dec 31, 2022−5.5%
Finished goods$427.0K4 Dec 31, 2023$3.2M4 Dec 31, 2022−86.8%

Leadership

Who has led G1 Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark A. Velleca2017–2020

President

  1. Mark A. Velleca2017–2020

Chief financial officer

  1. Barclay A. Phillips2017–2019
  2. Jennifer K. Moses2019–2023

Chief operating officer

  1. Terry L. Murdock2019–2024
20202025
Board members and other officers (24)

Former names

  • G-Zero Therapeutics, Inc.Oct 12, 2012 to Apr 18, 20132

Timeline

  1. Sep 18, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer39
  2. Aug 8, 20248-K Results of operations40
  3. Aug 7, 20248-K Entered a material agreement; Executive or director change; Other events41
  4. Jun 24, 20248-K Regulation FD disclosure42
  5. Jun 14, 20248-K Shareholder vote43
  6. May 1, 20248-K Results of operations44
  7. Mar 22, 20248-K Executive or director change45
  8. Feb 28, 20248-K Results of operations46
  9. Feb 12, 20248-K Other events47
  10. Jan 8, 20248-K Results of operations; Regulation FD disclosure48
  11. Nov 1, 20238-K Results of operations49
  12. Sep 21, 20238-K Executive or director change50
  13. May 16, 2017New chief executive Mark A. Velleca becomes CEO12

Calendar

When it reported results

  1. Aug 8, 2024Reported quarterly or annual results40
  2. May 1, 2024Reported quarterly or annual results44
  3. Feb 28, 2024Reported quarterly or annual results46
  4. Jan 8, 2024Reported quarterly or annual results48
  5. Nov 1, 2023Reported quarterly or annual results49
  6. Aug 2, 2023Reported quarterly or annual results51
  7. May 3, 2023Reported quarterly or annual results52
  8. Mar 1, 2023Reported quarterly or annual results53

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

209 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 32 major events, 107 insider forms, 12 large holders, 45 other. The latest 20:

  1. Nov 13, 2024SC 13G/A EDGAR
  2. Sep 30, 202415-12G EDGAR
  3. Sep 18, 2024S-8 POS EDGAR
  4. Sep 18, 2024S-8 POS EDGAR
  5. Sep 18, 2024S-8 POS EDGAR
  6. Sep 18, 2024S-8 POS EDGAR
  7. Sep 18, 2024S-8 POS EDGAR
  8. Sep 18, 2024S-8 POS EDGAR
  9. Sep 18, 2024S-8 POS EDGAR
  10. Sep 18, 20248-K EDGAR
  11. Sep 18, 2024SC 14D9/A EDGAR
  12. Sep 18, 2024SC TO-T/A EDGAR
  13. Sep 18, 20244 EDGAR
  14. Sep 18, 20244 EDGAR
  15. Sep 18, 20244 EDGAR
  16. Sep 18, 20244 EDGAR
  17. Sep 18, 20244 EDGAR
  18. Sep 18, 20244 EDGAR
  19. Sep 18, 20244 EDGAR
  20. Sep 18, 20244 EDGAR

The 209 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

55 open-market trades by officers, directors and large owners since October 2021: 0 buys and 55 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 5, 2024Perry AndrewChief Commercial OfficerSale1,337$2.51$3.4KForm 4
Jul 5, 2024MURDOCK TERRY LChief Operating OfficerSale2,475$2.51$6.2KForm 4
Jul 5, 2024Malik RajeshChief Medical OfficerSale2,475$2.51$6.2KForm 4
Jul 5, 2024Avagliano MarkChief Business OfficerSale2,638$2.51$6.6KForm 4
Jul 5, 2024Umstead John W. VChief Financial OfficerSale527$2.51$1.3KForm 4
Jul 5, 2024Bailey John E. (Jack) Jr.President and CEOSale7,662$2.51$19.2KForm 4
May 23, 2024Thomas Monica R.Chief Legal & People OfficerSale5,826$4.27$24.9KForm 4
May 13, 2024Perry AndrewChief Commercial OfficerSale8,151$4.79$39.0KForm 4
May 13, 2024Umstead John W. VChief Financial OfficerSale8,151$4.79$39.0KForm 4
May 13, 2024MURDOCK TERRY LChief Operating OfficerSale8,151$4.79$39.0KForm 4
May 13, 2024Malik RajeshChief Medical OfficerSale8,151$4.79$39.0KForm 4
May 13, 2024Avagliano MarkChief Business OfficerSale8,151$4.79$39.0KForm 4
May 13, 2024Bailey John E. (Jack) Jr.President and CEOSale37,258$4.79$178.5KForm 4
Mar 18, 2024Umstead John W. VChief Financial OfficerSale6,547$3.02$19.8KForm 4
Feb 12, 2024Malik RajeshChief Medical OfficerSale28,600$4.62$132.1KForm 4
Jan 4, 2024Umstead John W. VChief Financial OfficerSale111$2.94$326Form 4
Jan 4, 2024Malik RajeshChief Medical OfficerSale721$2.94$2.1KForm 4
Jan 4, 2024Avagliano MarkChief Business OfficerSale721$2.94$2.1KForm 4
Jan 4, 2024MURDOCK TERRY LChief Operating OfficerSale721$2.94$2.1KForm 4
Jan 3, 2024Umstead John W. VChief Financial OfficerSale632$3.12$2.0KForm 4

All 55 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How G1 Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARG1 Therapeutics, Inc.1
  • CIK0001560241
  • Employer ID (EIN)26-36481801
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address700 Park Offices Drive, Suite 200, Research Triangle Park, NC 277091
  • Phone919-213-98351
  • Shares outstanding52,758,191 as of Aug 2, 202410
  • Public float$127.5M as of Jun 30, 20234
  • On EDGAR sinceOct 12, 20121
  • Filings562 in all: 4 (278), 8-K (76), 3 (32), SC 13G/A (25), 10-Q (22), SC 13G (12), 10-K (7), DEF 14A (7)1
    All 48 form types

    S-8 (7), S-8 POS (7), 144 (6), CORRESP (6), DEFA14A (6), D (5), UPLOAD (5), 3/A (4), 424B5 (4), D/A (3), EFFECT (3), S-1/A (3), SC 14D9/A (3), SC14D9C (3), 10-K/A (2), 424B4 (2), ARS (2), CT ORDER (2), DRS (2), DRS/A (2), DRSLTR (2), S-1 (2), S-1MEF (2), S-3ASR (2), SC TO-C (2), SC TO-T/A (2), 15-12G (1), 25-NSE (1), 4/A (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), POS AM (1), POSASR (1), PRE 14A (1), SC 13D (1), SC 13D/A (1), SC 14D9 (1), SC TO-T (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2024
    Quarterly report (10-Q) Aug 8, 2024
    Proxy statement (DEF 14A) Apr 25, 2024
    Latest 8-K (8-K) Sep 18, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59